Benefits
CD38 Inhibition / NAD+ Preservation (Theoretical)
CD38 enzyme degrades NAD+ — apigenin inhibits CD38 in vitro and in animal models, theoretically preserving NAD+ levels. Component of longevity protocols seeking to maintain age-related NAD+ decline. Clinical translation in humans not definitively established.
Anxiolytic / Calming Effects
Apigenin binds GABA-A benzodiazepine receptor with modest affinity — basis for chamomile's traditional calming use. Amsterdam 2009 trial of chamomile (containing apigenin) showed modest anxiolytic benefit in generalized anxiety disorder vs placebo.
Sleep Support
Chamomile traditionally used for sleep; apigenin contributes via GABA-A receptor activity and circadian effects. Modest sleep onset latency reduction in some trials. Adler 2011 chamomile trial showed sleep quality improvement in elderly.
Anti-Inflammatory / Antioxidant
Inhibits NF-κB, COX-2, iNOS in vitro — broad anti-inflammatory profile. Free radical scavenging activity. Component of multi-mechanism cardiovascular and longevity supplementation.
Cancer Chemoprevention Research
Extensive in vitro evidence for apoptosis induction in cancer cell lines (breast, prostate, colon, lung); animal models show tumor growth inhibition. Human clinical translation limited; not established cancer therapy.
Mechanism of action
CD38 Inhibition (NAD+ Pathway)
CD38 is the major NAD+-degrading enzyme; CD38 expression increases with age, contributing to NAD+ decline. Apigenin inhibits CD38 in vitro and animal studies — theoretical NAD+ preservation. Mechanism makes apigenin popular in NMN/NR/longevity stacks. Note: in vitro CD38 IC50 is in micromolar range; achievable plasma levels with oral supplementation are typically nanomolar — clinical CD38 inhibition uncertain.
GABA-A Benzodiazepine Receptor Modulation
Apigenin is a ligand at the benzodiazepine site of the GABA-A receptor — mild positive allosteric modulator. Lower potency than pharmaceutical benzodiazepines but contributes to anxiolytic/calming effects. Basis for chamomile's traditional calming use.
Aromatase Inhibition
Apigenin modestly inhibits aromatase enzyme (CYP19) — the enzyme that converts androgens to estrogens. Theoretical implications for hormone-sensitive conditions; clinical relevance modest at typical supplemental doses.
NF-κB and Inflammatory Pathway Inhibition
Modulates NF-κB signaling, reduces COX-2 and iNOS expression. Broad anti-inflammatory profile basis for chronic inflammation contexts.
Clinical trials
RCT of standardized chamomile extract vs placebo in patients with mild-to-moderate generalized anxiety disorder for 8 weeks.
57 patients with GAD.
Chamomile extract significantly reduced anxiety scores (Hamilton Anxiety Rating Scale) vs placebo. Effect modest. Apigenin contributes to but is not solely responsible for chamomile's effects.
Multiple preclinical studies of apigenin's CD38 inhibition and NAD+ preservation effects in cell culture and animal models.
Cell culture and rodent models.
Apigenin inhibits CD38 in vitro and increases NAD+ in tissues of treated animals. Translates to improved metabolic markers. Human clinical trials testing CD38 inhibition / NAD+ preservation with apigenin specifically are LIMITED — popularized largely from preclinical mechanism plus longevity protocols.
About this ingredient
Apigenin (4',5,7-trihydroxyflavone) is a FLAVONE found abundantly in PARSLEY (the highest dietary source), chamomile, celery, artichoke, oregano, basil. Distinguished from other flavonoids by aglycone form (no sugar attached) and specific receptor binding properties.
SOURCES & CONCENTRATIONS: dried parsley ~4,500 mg/100g; chamomile flowers ~3-5%; celery ~108 mg/100g; artichoke ~7.5 mg/100g. CHAMOMILE TEA provides ~1-3 mg apigenin per cup. SUPPLEMENT FORMS: standalone apigenin (50-100 mg capsules), parsley-derived extract, chamomile extracts. Bryan Johnson 'Blueprint' protocol features apigenin 50 mg/day as longevity intervention — has popularized this ingredient.
EVIDENCE-BASED USES: (1) ANXIETY / CALMING — chamomile-based clinical evidence (Amsterdam 2009); GABA-A benzodiazepine receptor mechanism; (2) SLEEP support; (3) Anti-inflammatory; (4) Antioxidant. EMERGING / SPECULATIVE: (5) NAD+ PRESERVATION via CD38 inhibition — preclinical mechanism interesting; human clinical translation unclear; popularized by longevity protocols rather than rigorous trials; (6) CANCER CHEMOPREVENTION — preclinical evidence extensive; clinical not established.
CRITICAL CAUTIONS: (1) ASTERACEAE ALLERGY — apigenin (and chamomile) may cross-react with ragweed, daisy, chrysanthemum, marigold allergies; if Asteraceae-allergic, use with caution; (2) PREGNANCY/LACTATION — chamomile traditionally avoided in pregnancy due to theoretical emmenagogue effects; supplemental apigenin lacks pregnancy safety data; AVOID; (3) BENZODIAZEPINE / SEDATIVE COMBINATION — additive CNS depression; theoretical at supplemental doses; caution; (4) PRE-SURGERY — discontinue 1-2 weeks before surgery (theoretical bleeding/sedation concerns); (5) HORMONE-SENSITIVE CONDITIONS — modest aromatase inhibition is unlikely clinically significant at typical doses but theoretical; consult oncologist if relevant; (6) BIOAVAILABILITY — apigenin oral bioavailability is LOW (likely <5%); achieving plasma concentrations sufficient for in vitro mechanisms (especially CD38 inhibition at micromolar levels) is uncertain with oral dosing; (7) DOSE — 50 mg/day common in longevity protocols; up to 100 mg/day used; clinical dose-response data limited; (8) CD38 INHIBITION CLAIMS — based largely on in vitro and animal studies; if NAD+ preservation is goal, NMN/NR have stronger direct evidence; apigenin is adjunctive at most; (9) CHAMOMILE TEA provides modest apigenin plus other compounds; for general anxiolytic/sleep support, chamomile tea may be sufficient and is well-established traditionally; (10) BIOAVAILABILITY ENHANCERS — co-administered fats, piperine, or quercetin may modestly improve apigenin absorption; relevant for those pursuing CD38 inhibition mechanism.